Although cisplatin is an effective platinum-based anticancer drug against solid cancer, its availability is limited owing to its adverse side effects. Our study aimed to identify the potential relationship within cisplatin-induced multi-organ physiological changes and genetic factors associated with sex differences in nephrotoxicity susceptibility. To investigate this, mice received a single intraperitoneal injection of cisplatin. Cisplatin administration resulted in renal dysfunction, as evidenced by the elevation in serum biomarkers of renal damage (blood urea nitrogen and creatinine) and the degree of histopathological alterations. In particular, along with testicular damage and low testosterone levels, we also observed a decrease in male-specific (CYP3A2) or male-dominant (CYP2B1 and CYP3A1) CYP isoforms in the livers of rats with hepatotoxicity following cisplatin treatment, which may be associated with an imbalance in male hormone regulation caused by renal and testicular injury. Notably, we found that male rats were more susceptible to cisplatin-induced nephrotoxicity, as characterized by histopathological and biochemical analyses. Therefore, RNA sequencing was performed at baseline (pre-treatment) and at 48 h following cisplatin administration (post-treatment) to identify the genes associated with sex differences in nephrotoxicity susceptibility. Gap junctions, which play a role in replenishing damaged cells to maintain tissue homeostasis, and mismatch repair associated with a pathological apoptotic mechanism against cisplatin nephrotoxicity were significantly enriched only in males following cisplatin treatment. Moreover, among the 322 DEGs showing different basal expression patterns between males and females before cisplatin treatment, the male expressed high levels of genes, which are responsible for transmembrane transport and regulation of apoptotic process, pre-cisplatin treatment; additionally, genes involved in the PI3K-Akt signaling pathway and the oxidation-reduction process were significantly lower in males before cisplatin treatment. Collectively, our comprehensive findings provided valuable insight into the potential mechanisms of sex differences in cisplatin-induced nephrotoxicity susceptibility.
机构:
US FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USAUS FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Espandiari, P.
Rosenzweig, B.
论文数: 0引用数: 0
h-index: 0
机构:US FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Rosenzweig, B.
Zhang, J.
论文数: 0引用数: 0
h-index: 0
机构:US FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Zhang, J.
Zhou, Y.
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USAUS FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Zhou, Y.
Schnackenberg, L.
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Natl Ctr Toxicol Res, Jefferson, AR USAUS FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Schnackenberg, L.
Vaidya, V. S.
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Univ, Sch Med, Boston, MA 02115 USAUS FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Vaidya, V. S.
Goering, P. L.
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USAUS FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Goering, P. L.
Brown, R. P.
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USAUS FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Brown, R. P.
Bonventre, J. V.
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Univ, Sch Med, Boston, MA 02115 USAUS FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Bonventre, J. V.
Mahjoob, K.
论文数: 0引用数: 0
h-index: 0
机构:US FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Mahjoob, K.
Holland, R. D.
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Natl Ctr Toxicol Res, Jefferson, AR USAUS FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Holland, R. D.
Beger, R. D.
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Natl Ctr Toxicol Res, Jefferson, AR USAUS FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Beger, R. D.
Thompson, K.
论文数: 0引用数: 0
h-index: 0
机构:US FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Thompson, K.
Hanig, J.
论文数: 0引用数: 0
h-index: 0
机构:US FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Hanig, J.
Sadrieh, N.
论文数: 0引用数: 0
h-index: 0
机构:US FDA, Div Appl Pharmacol Res HFD 910, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
机构:
Univ Med Sci, Water & Electrolytes Res Ctr, Esfahan, Iran
Islamic Azad Univ, Dept Biol, Falavarjan Branch, Esfahan, IranUniv Med Sci, Water & Electrolytes Res Ctr, Esfahan, Iran
Ghadirian, Fereshteh
Nematbakhsh, Mehdi
论文数: 0引用数: 0
h-index: 0
机构:
Univ Med Sci, Water & Electrolytes Res Ctr, Esfahan, Iran
Univ Med Sci, Dept Physiol, Esfahan, Iran
Isfahan MN Inst Basic & Appl Sci Res, Esfahan, IranUniv Med Sci, Water & Electrolytes Res Ctr, Esfahan, Iran
Nematbakhsh, Mehdi
Roozbehani, Shahla
论文数: 0引用数: 0
h-index: 0
机构:
Islamic Azad Univ, Dept Biol, Falavarjan Branch, Esfahan, IranUniv Med Sci, Water & Electrolytes Res Ctr, Esfahan, Iran
Roozbehani, Shahla
Mazaheri, Safoora
论文数: 0引用数: 0
h-index: 0
机构:
Univ Med Sci, Water & Electrolytes Res Ctr, Esfahan, IranUniv Med Sci, Water & Electrolytes Res Ctr, Esfahan, Iran
Mazaheri, Safoora
Talebi, Ardeshir
论文数: 0引用数: 0
h-index: 0
机构:
Univ Med Sci, Dept Clin Pathol, Esfahan, IranUniv Med Sci, Water & Electrolytes Res Ctr, Esfahan, Iran
Talebi, Ardeshir
Pezeshki, Zahra
论文数: 0引用数: 0
h-index: 0
机构:
Univ Med Sci, Water & Electrolytes Res Ctr, Esfahan, IranUniv Med Sci, Water & Electrolytes Res Ctr, Esfahan, Iran